Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III LIBERTY CUPID Clinical Program for Chronic Spontaneous Urticaria

 Regeneron and Sanofi Report Results of Dupixent (dupilumab) in P-III LIBERTY CUPID Clinical Program for Chronic Spontaneous Urticaria

Shots:

  • The study A of P-III LIBERTY CUPID trial evaluates Dupixent vs SoC in 138 patients aged ≥6 yrs. with CSU who remained symptomatic despite antihistamine use and who were not previously treated with anti-IgE therapeutics
  • The trial met its 1EPs & 2EPs @24wks. i.e. showed a reduction in itch severity (63% vs 35%), reduction in urticaria activity (itch and hives) severity (65% vs 37%) while safety results were like the known safety profile of Dupixent
  • The ongoing Study B evaluates Dupixent in adults & adolescents who remain symptomatic despite SOC treatment and are intolerant or incomplete responders to omalizumab with its expected results in H1’22. The companies plan to start regulatory submissions in 2022

Click here to read full press release/ article | Ref: Regeneron| Image: Clinical Trials Arena

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post